No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration with emtricitabine/tenofovir-DF has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anion and cation transporters. No interaction is expected with emtricitabine and no significant pharmacokinetic interactions were observed when tenofovir-DF (300 mg once daily) was coadministered with entecavir (1 mg once daily). There was no change in entecavir Cmax or Cmin; however, entecavir AUC increased by 13%.
Coadministration of entecavir (1 mg once daily) and tenofovir-DF (300 mg once daily) had no effect on entecavir Cmax or Cmin, but increased AUC by 13% (n=28).
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking